Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from STAA

Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition

On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL).

Are the new government rules on short-term lets just "more hot air" for London's renters?

Homeowners who rent out their homes for more than 90 days a year will need to seek planning permission, but London already caps short term lets at that limit

Evening Standard

S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms

S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms

S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

IBD Stock Of The Day Staar Surgical Is Pulling Back — Why You Should Pay Attention

Staar Surgical is the IBD Stock Of The Day. Although STAA stock isn't actionable, shares have weathered a tricky second quarter.

Investors Business Daily

Staar Obliterates Earnings Forecasts Again — And Tacks On Another Sales Beat

Staar Surgical reported better-than-expected second-quarter metrics, leading STAA stock to soar to a nine-month high Thursday.

Investors Business Daily

Here's How Much You Would Have Made Owning Staar Surgical Stock In The Last 20 Years

Staar Surgical (NASDAQ:STAA) has outperformed the market over the past 20 years by 5.45% on an annualized basis producing an average annual return of 12.6%. Currently, Staar Surgical has a market capitalization of $2.88 billion.

Needham Sees Clear View Into STAAR Surgical's Durable Double-Digit Revenue Expansion

Needham is initiating coverage on STAAR Surgical Company (NASDAQ:STAA) with a Buy rating and an $87 price target. The analysts note that FDA approval of STAA's EVO Implantable Collamer Lens (ICLs) should serve as a meaningful tailwind for revenue. The Company generates most of its revenue from outside US markets. But after the FDA approval…

inkl

Read news from The Economist, FT, and more,
with one subscription

Why STAAR Surgical's Shares Are Gaining Today

Why STAAR Surgical's Shares Are Gaining Today

The FDA approved STAAR Surgical Company's (NASDAQ:STAA) EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for distance vision correction. The Company, in a statement, says that the EVO lens is additive, provides quality of vision day & night, does not cause…

Staar Surgical Rockets After FDA Clears Its Implantable Lens For Nearsightedness

Staar Surgical Rockets After FDA Clears Its Implantable Lens For Nearsightedness

Staar Surgical won Food and Drug Administration clearance for its implantable nearsightedness lens on Monday, leading STAA stock to soar.

Investors Business Daily

BTIG Upgraded Staar Surgical Stock - Read Why

BTIG Upgraded Staar Surgical Stock - Read Why

BTIG upgraded Implantable lenses-focused Staar Surgical Company (NASDAQ: STAA) to Buy from Neutral with a $98 price target.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Palo Alto Networks

Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

304,021 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play